JOSEPH C. PAPA - 06 Mar 2025 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Role
President and CEO, Director
Signature
/s/ Richard S. Lindahl, Attorney-in-fact
Issuer symbol
EBS
Transactions as of
06 Mar 2025
Transactions value $
$0
Form type
4
Filing time
10 Mar 2025, 16:17:31 UTC
Previous filing
05 Sep 2024
Next filing
12 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EBS Common Stock Award $0 +282,500 $0 282,500 06 Mar 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EBS Employee Stock Options (Right to Buy) Award $0 +282,500 +38% $0 1,032,500 06 Mar 2025 Common Stock 282,500 $5.8 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each performance stock unit represents a right to receive one share of common stock. The performance stock units vest in three annual installments beginning on the day prior to the anniversary of the date of grant, assuming continued service with the company and upon achievement with respect to Adjusted EBITDA for the 2025 fiscal year, as certified by the Compensation Committee following the performance period.
F2 Vests in three equal installments beginning on the day prior to the anniversary date of the grant.